Adverum Biotechnologies: Gene Therapy Company And Our New … – Seeking Alpha
Seeking Alpha |
Adverum Biotechnologies: Gene Therapy Company And Our New …
Seeking Alpha The stock is at an attractive entry point ahead of phase I/II data from a gene therapy trial in alpha-1 antitrypsin deficiency in the second half of this year. We are rating the stock a Buy with price target = $18. We bought shares of Adverum … Adverum Biotechnologies, Inc. (ADVM) Declined to $5.45 on Apr, 8Houston Style On Fleek What’s Adverum Biotechnologies, Inc. (ADVM) Downside After Today’s Significant Decline?NMSU Herald Zacks Premium Investment Service – Zacks.comZacks |
StocksGeeks (press release) |
CRISPR Is Already Changing Our World, Here’s How
ScienceAlert Even if you have no idea how it works or what the letters stand for, chances are you’ve at least heard of the revolutionary technology dubbed CRISPR. Cheaper and far more precise than previous gene-editing processes, the CRISPR/Cas9 molecular toolkit … Healthcare Stock in Focus: CRISPR Therapeutics AG (CRSP)StocksGeeks (press release) CRISPR Therapeutics (CRSP) Is Now Covered By Goldman Sachs. What can We Expect?Frisco Fastball CRISPR Therapeutics (CRSP) Receives New Coverage from Analysts at Goldman SachsMacon Daily NMSU Herald –BZ Weekly –The Lincolnian Online all 8 news articles » |